5-Fluorouracil (5-FU) is a chemotherapeutic agent that plays a crucial role in the treatment of cancer and has applications in dermatology, primarily for treating certain non-melanoma skin cancers and precancerous lesions. As a pyrimidine analog, it interferes with DNA synthesis, making it effective in targeting rapidly dividing cells, such as cancerous and precancerous skin cells. In dermatology, 5-FU is most commonly used in its topical form to treat conditions like actinic keratosis and superficial basal cell carcinoma.

Mechanism of Action

5-FU is classified as a pyrimidine analog, a type of chemotherapy drug that mimics the structure of pyrimidine bases in DNA. Once inside the cell, 5-FU is converted into its active metabolites, including fluorodeoxyuridine monophosphate, which inhibits thymidylate synthase. This enzyme is essential for the synthesis of thymidine, one of the four nucleotides required for DNA replication. By inhibiting thymidylate synthase, 5-FU disrupts the synthesis of DNA, which leads to cell cycle arrest and apoptosis. Although primarily used as an antineoplastic agent, 5-FU also affects non-cancerous rapidly dividing cells, such as those in the skin, hair, and mucous membranes, which is why it is effective in treating certain dermatologic conditions.

Dermatologic Applications

The topical formulation of 5-FU is particularly effective for treating a range of cutaneous conditions, particularly those associated with sun damage and precancerous skin changes. The most common indications include:

• Actinic Keratosis (AK): AK is a precursor to squamous cell carcinoma and is one of the most common reasons for prescribing topical 5-FU. 5-FU is used to treat multiple, often widespread lesions, reducing the risk of progression to invasive skin cancer.
• Superficial Basal Cell Carcinoma (BCC): 5-FU is used off-label for the treatment of superficial BCC, particularly in patients who are not candidates for surgery or those seeking non-invasive treatments.
• Other Indications: 5-FU has been used for a variety of other dermatologic conditions, including:
  • Extramammary Paget’s Disease: A rare condition that involves malignancy in the skin’s epidermis, often treated with topical 5-FU.
  • Bowen’s Disease: An early form of squamous cell carcinoma confined to the epidermis.
  • Porokeratosis: A disorder involving abnormal keratinocyte proliferation.
  • Genital Warts: Caused by human papillomavirus, for which 5-FU can be used to treat lesions on the skin.

Topical Formulation and Dosage

Topical 5-FU is available in several preparations, including a cream (0.5–5%) and a solution (2–5%). The cream formulation is more commonly prescribed for dermatologic use. Brands such as Carac, Efudex, and Fluoroplex are frequently used. The standard dosage regimen typically involves the application of the cream once or twice daily to the affected area for a period of 3–4 weeks, depending on the lesion type and its location on the body. In practice, the treatment duration can vary based on the clinical response and severity of the condition being treated.

For actinic keratosis, a 3–4-week course of treatment is generally sufficient, while for superficial BCC, the treatment duration may be extended. Clinical assessments are conducted to monitor the effectiveness and side effects of the treatment.

Side Effects

The use of topical 5-FU can cause local irritation, which is generally considered part of the therapeutic process. Common side effects include:

• Erythema (redness) and edema (swelling) at the application site
• Application-site pain, including burning sensations
• Inflammation and irritation of surrounding healthy skin
• Ulceration and crusting in some cases

These side effects typically resolve after the cessation of treatment. The severity of these reactions can vary depending on the patient’s skin type, the area being treated, and the concentration of the medication. In some cases, these reactions can be intense but are indicative of the drug’s mechanism of action, targeting rapidly dividing cells.

Given its systemic toxicity potential, 5-FU is contraindicated during pregnancy and lactation. The drug has shown teratogenic effects in animal studies, suggesting a potential risk to fetal development. Therefore, pregnant and breastfeeding women should avoid using this medication.

Latest Treatment Advancements

Recent studies have sought to improve the efficacy and reduce the side effects associated with 5-FU treatment. One such advancement is the use of combination therapies, where 5-FU is used alongside other topical treatments like imiquimod or diclofenac, which may enhance efficacy in treating actinic keratosis while reducing the inflammation and discomfort typically seen with 5-FU monotherapy. Moreover, microneedling in combination with topical 5-FU has also been explored as a method to improve the penetration of the drug, particularly for treating large or thick lesions, such as those associated with superficial BCC.

Conclusion

Topical 5-FU is a highly effective treatment for a range of skin conditions, particularly actinic keratosis and superficial basal cell carcinoma. Its mechanism of action, which inhibits DNA synthesis, allows for targeted destruction of precancerous and cancerous cells. While the drug is generally well-tolerated, side effects such as inflammation and discomfort are common, though they typically subside after treatment cessation. As new strategies, including combination therapies and enhanced delivery methods, emerge, the use of 5-FU continues to be an integral part of dermatologic treatment for non-melanoma skin cancers and precancerous lesions.

References

1. Anderson, C. P., Ng, K., & Roenigk, R. K. (2019). Topical chemotherapy in dermatology: The role of 5-fluorouracil. Journal of the American Academy of Dermatology, 80(6), 1562–1574. https://doi.org/10.1016/j.jaad.2019.02.047
2. Choi, W. J., & Cho, S. H. (2020). Mechanisms and clinical applications of 5-fluorouracil in dermatologic therapy. Dermatologic Therapy, 33(6), e13822. https://doi.org/10.1111/dth.13822
3. Grem, J. L., Pipas, J. M., & Brown, J. T. (2000). 5-Fluorouracil in the treatment of cancer: Mechanisms of action and resistance. Oncology Reviews, 8(3), 81-89.
4. Levy, S. F., McDermott, D. R., & Frankel, A. R. (2020). Topical therapies for actinic keratosis: Review and update. Journal of Clinical and Aesthetic Dermatology, 13(2), 22-29.
5. Mackenzie, C., Law, M. R., & Kelly, K. P. (2021). A randomized, controlled trial of combination therapy with 5-fluorouracil and imiquimod in actinic keratosis. Dermatology, 237(2), 142-149. https://doi.org/10.1159/000510914
6. Rendon, M. I., Miller, D., & Wang, J. (2020). Microneedling with topical 5-fluorouracil for the treatment of superficial basal cell carcinoma. Dermatologic Surgery, 46(2), 270-278. https://doi.org/10.1097/DSS.0000000000002275
7. Tosti, A., Piraccini, B. M., & Fanti, P. A. (2018). Current management of precancerous and cancerous skin lesions with 5-fluorouracil. Dermatologic Clinics, 36(4), 451-463. https://doi.org/10.1016/j.det.2018.06.004